Safety and efficacy of resmetirom in the treatment of patients with non-alcoholic steatohepatitis and liver fibrosis: a systematic review and meta-analysis.

Ann Med Surg (Lond) · 2024 · PMC11230798 · PMID 38989228

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

Conclusion Resmetirom exhibited a notable trend in reducing hepatic fat fraction compared to placebo, as evidenced by MRI-PDFF at 52 weeks.

also in 2,380 other papers

a significant trendno p-value reported

Our analysis showed a significant trend towards fat reduction in the group that was administered with resmetirom as compared to the placebo group.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.